← ANALYST RATINGS · TIPRANKS

Emergent Biosolutions (EBS): analyst forecast and price target

$6.38 −11.14% close 16.10.26 · market cap $368M · Healthcare · Drug Manufacturers - Specialty & Generic IWM 0.01%
Price targets and ratings of

Analyst consensus

Hold

1 Buy0 Hold1 Sell

Ratings of 2 analysts in the last 3 months · top analysts only

12-month forecast

$10.00+56.7% upside

Based on 2 price targets given in the last 3 months, the average target is $10.00, the highest $10.00, the lowest $10.00. The average is +56.7% from the last price of $6.38.

$5.00$10.00Jan 26AprJulOctJan 27AprJulOctHigh$10.00Average$10.00Low$10.00
Highest target $10.00 Average target $10.00 Lowest target $10.00
AnalystFirmPrice target RatingUpsideAction Date Move vs SPY
Ram Selvaraju★★★★★★★★★★#212 · hits 57% · avg +24.4% H.C. Wainwright $10.00 Buy +56.7% Reiterated 09.09.26on TipRanks 06:55 −4.9%next day +3.9% · 5 days +19.9%
Jessica Fye★★★★★★★★★★#1182 · hits 56% · avg +9.4% J.P. Morgan — Sell — Initiated 21.08.26on TipRanks 06:43 +5.0%next day +2.3% · 5 days +15.9%

Every rating the collector has kept for the last 12 months, including the earlier ones of the same analyst. Latest of each analyst

Best analysts covering Emergent Biosolutions

TipRanks picks them by their record on this stock; the figures under the name are their record across all their ratings.

Most accurate

3 months Ram Selvaraju★★★★★★★★★★H.C. Wainwright · #212
Hits 57%287 of 500 Average return +24.4%
1 year Ram Selvaraju★★★★★★★★★★H.C. Wainwright · #212
Hits 57%287 of 500 Average return +24.4%
2 years Ram Selvaraju★★★★★★★★★★H.C. Wainwright · #212
Hits 57%287 of 500 Average return +24.4%

Most profitable

3 months Ram Selvaraju★★★★★★★★★★H.C. Wainwright · #212
Hits 57%287 of 500 Average return +24.4%
1 year Ram Selvaraju★★★★★★★★★★H.C. Wainwright · #212
Hits 57%287 of 500 Average return +24.4%
2 years Ram Selvaraju★★★★★★★★★★H.C. Wainwright · #212
Hits 57%287 of 500 Average return +24.4%

How the average price target moved

The average target of all analysts (their ratings of the 3 months before) on each day, the top analysts’ dashed, against the price; the site keeps this record since 1 October 2026. On 01.10.26: target $10.00 at a price of $6.60 (+51.5%); now: $10.00 at $6.38 (+56.7%).

$6.00$8.00$10.00Sep 15Oct 1Oct 15Top analysts$10.00Average target$10.00Price$6.38

PriceAverage targetTop analysts’ target

Recommendation trend · top analysts

024652Oct 2542Nov3Dec4Jan 263Feb4Mar13Apr14May13Jun2Jul111Aug21Sep21Oct

Strong BuyBuyHoldSell

Rating05.2606.2607.2608.2609.2610.26
Strong Buy110122
Buy432100
Hold000000
Sell000111

Earnings and sales forecast

Next report: 02.11.26 (Q3 2026, date not confirmed)

Earnings per share

Next quarter’s EPS estimate — $-0.39 (from $-0.41 to $-0.37). Last quarter: $0.60.

Sales

Next quarter’s sales estimate — $123M (from $118M to $129M). Last quarter: $234M.

Best top-analyst consensus in the sector · Healthcare

OVIDOvid Therapeutics
AXGNAxoGen
PTGXProtagonist TherapeuticsStrong Buy
ESTAEstablishment Labs HoldingsStrong Buy
REPLReplimune GroupStrong Buy
About Emergent Biosolutions

Emergent BioSolutions Inc. is a life sciences company dedicated to providing vital preparedness and response solutions for a wide range of public health threats (PHTs) across the United States. These threats encompass accidental, deliberate, and naturally occurring events, including chemical, biological, radiological, nuclear, and explosives (CBRNE) incidents, emerging infectious diseases, travel-related health risks, and acute emergency care situations. The company's current product portfolio features essential vaccines and treatments such as BioThrax for anthrax and ACAM2000 for smallpox. It also offers Botulism Antitoxin Heptavalent, vaccinia immune globulin intravenous to manage smallpox vaccine complications, and inhalational anthrax therapies like raxibacumab and Anthrasil. Other key offerings include reactive skin decontamination lotion kits, the Trobigard combination drug-device auto-injector, NARCAN nasal spray for emergency opioid overdose reversal, Vivotif, an oral typhoid fever vaccine, and Vaxchora, a single-dose oral cholera vaccine. Emergent is also actively engaged in developing a robust pipeline of future solutions. This includes AP003 (a multidose naloxone nasal spray), AP007 (a sustained-release nalmefene injection for opioid use disorder), AV7909 (an anthrax vaccine), CGRD-001 (a pralidoxime chloride/atropine auto-injector), CHIKV VLP (a chikungunya virus vaccine), COVID-HIG (for SARS-CoV2 treatment), EGRD-001 (a diazepam auto-injector), SIAN (a cyanide poisoning antidote), and UniFlu (a universal influenza vaccine). Furthermore, the company extends its expertise through comprehensive contract development and manufacturing services (CDMO). These services cover drug substance and product manufacturing, packaging, along with technology transfer and advanced process and analytical development. Emergent BioSolutions Inc., founded in 1998, is headquartered in Gaithersburg, Maryland.

Data from the stock’s TipRanks forecast page, read 242 min ago. It is read again as soon as a new rating appears and at least every 8 hours. TipRanks ↗